Heterologous vector-mRNA based SARS-CoV-2 vaccination strategy appears superior to a homologous vector-based vaccination scheme in German healthcare workers regarding humoral SARS-CoV-2 response indicating a high boosting effect by mRNA vaccines

Background: Longitudinal humoral SARS-CoV-2 (severe acute respiratory syndrome coronavirus type 2) immunity for up to 15 months due to vaccination, the efficacy of vaccination strategies (homologous, vector-vector versus heterologous, vector-mRNA), the influence of vaccination side effects, and the...

Full description

Saved in:
Bibliographic Details
Main Authors: Gerhards, Catharina (Author) , Thiaucourt, Margot (Author) , Hetjens, Michael (Author) , Haselmann, Verena (Author) , Neumaier, Michael (Author) , Kittel, Maximilian (Author)
Format: Article (Journal)
Language:English
Published: 19 March 2023
In: Vaccines
Year: 2023, Volume: 11, Issue: 3, Pages: 1-17
ISSN:2076-393X
DOI:10.3390/vaccines11030701
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.3390/vaccines11030701
Verlag, kostenfrei, Volltext: https://www.mdpi.com/2076-393X/11/3/701
Get full text
Author Notes:Catharina Gerhards, Margot Thiaucourt, Michael Hetjens, Verena Haselmann, Michael Neumaier and Maximilian Kittel

MARC

LEADER 00000caa a2200000 c 4500
001 1897205376
003 DE-627
005 20241205155550.0
007 cr uuu---uuuuu
008 240731s2023 xx |||||o 00| ||eng c
024 7 |a 10.3390/vaccines11030701  |2 doi 
035 |a (DE-627)1897205376 
035 |a (DE-599)KXP1897205376 
035 |a (OCoLC)1475305171 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Gerhards, Catharina  |d 1992-  |e VerfasserIn  |0 (DE-588)1226262503  |0 (DE-627)1747234710  |4 aut 
245 1 0 |a Heterologous vector-mRNA based SARS-CoV-2 vaccination strategy appears superior to a homologous vector-based vaccination scheme in German healthcare workers regarding humoral SARS-CoV-2 response indicating a high boosting effect by mRNA vaccines  |c Catharina Gerhards, Margot Thiaucourt, Michael Hetjens, Verena Haselmann, Michael Neumaier and Maximilian Kittel 
264 1 |c 19 March 2023 
300 |b Illustrationen 
300 |a 17 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 31.07.2024 
520 |a Background: Longitudinal humoral SARS-CoV-2 (severe acute respiratory syndrome coronavirus type 2) immunity for up to 15 months due to vaccination, the efficacy of vaccination strategies (homologous, vector-vector versus heterologous, vector-mRNA), the influence of vaccination side effects, and the infection rate in German healthcare workers need to be investigated. Methods: In this study, 103 individuals vaccinated against SARS-CoV-2 were enrolled to examine their anti-SARS-CoV-2 anti-N- and anti-RBD/S1-Ig levels. A total of 415 blood samples in lithium heparin tubes were prospectively obtained, and a structured survey regarding medical history, type of vaccine, and vaccination reactions was conducted. Results: All participants demonstrated a humoral immune response, among whom no values decreased below the positivity cutoff. Five to six months after the third vaccination, three participants showed anti-RBD/S1 antibodies of less than 1000 U/mL. We observed higher levels for heterologous mRNA-/vector-based combinations compared to pure vector-based vaccination after the second vaccination, which is harmonized after a third vaccination with the mRNA-vaccine only in both cohorts. The incidence of vaccine breakthrough in a highly exposed cohort was 60.3%. Conclusion: Sustained long-term humoral immunity was observed, indicating the superiority of a heterologous mRNA-/vector-based combination compared to pure vector-based vaccination. There was longevity of anti-RBD/S1 antibodies of at least 4 and up to 7 months without external stimulus. Regarding vaccination reactogenity, the occurrence of local symptoms as pain at the injection site was increased after the first mRNA application compared to the vector-vector cohort with a general decrease in adverse events at later vaccination time points. Overall, a correlation between the humoral vaccination response and vaccination side effects was not observed. Despite the high prevalence of vaccine breakthroughs, these only occurred in the later course of the study when more infectious variants, which are, however, associated with milder courses, were present. These results provide insights into vaccine-related serologic responses, and the study should be expanded using additional vaccine doses and novel variants in the future. 
650 4 |a anti-SARS-CoV-2 antibodies 
650 4 |a antibody dynamics 
650 4 |a antibody kinetics 
650 4 |a humoral response post-vaccination 
650 4 |a longitudinal assessment 
650 4 |a serological immune response 
650 4 |a side effects 
650 4 |a vaccination breakthrough 
650 4 |a vaccination strategy 
700 1 |a Thiaucourt, Margot  |d 1993-  |e VerfasserIn  |0 (DE-588)1156311373  |0 (DE-627)1018863850  |4 aut 
700 1 |a Hetjens, Michael  |d 1963-  |e VerfasserIn  |0 (DE-588)1239761503  |0 (DE-627)1767848471  |4 aut 
700 1 |a Haselmann, Verena  |d 1982-  |e VerfasserIn  |0 (DE-588)1153803097  |0 (DE-627)1015321275  |0 (DE-576)500568154  |4 aut 
700 1 |a Neumaier, Michael  |d 1958-  |e VerfasserIn  |0 (DE-588)1028284934  |0 (DE-627)730532623  |0 (DE-576)375780580  |4 aut 
700 1 |a Kittel, Maximilian  |d 1987-  |e VerfasserIn  |0 (DE-588)1156691699  |0 (DE-627)1019529741  |0 (DE-576)502380136  |4 aut 
773 0 8 |i Enthalten in  |t Vaccines  |d Basel : MDPI, 2013  |g 11(2023), 3 vom: März, Artikel-ID 701, Seite 1-17  |h Online-Ressource  |w (DE-627)736559205  |w (DE-600)2703319-3  |w (DE-576)37898585X  |x 2076-393X  |7 nnas  |a Heterologous vector-mRNA based SARS-CoV-2 vaccination strategy appears superior to a homologous vector-based vaccination scheme in German healthcare workers regarding humoral SARS-CoV-2 response indicating a high boosting effect by mRNA vaccines 
773 1 8 |g volume:11  |g year:2023  |g number:3  |g month:03  |g elocationid:701  |g pages:1-17  |g extent:17  |a Heterologous vector-mRNA based SARS-CoV-2 vaccination strategy appears superior to a homologous vector-based vaccination scheme in German healthcare workers regarding humoral SARS-CoV-2 response indicating a high boosting effect by mRNA vaccines 
856 4 0 |u https://doi.org/10.3390/vaccines11030701  |x Verlag  |x Resolving-System  |z kostenfrei  |3 Volltext 
856 4 0 |u https://www.mdpi.com/2076-393X/11/3/701  |x Verlag  |z kostenfrei  |3 Volltext 
951 |a AR 
992 |a 20240731 
993 |a Article 
994 |a 2023 
998 |g 1156691699  |a Kittel, Maximilian  |m 1156691699:Kittel, Maximilian  |d 60000  |e 60000PK1156691699  |k 0/60000/  |p 6  |y j 
998 |g 1028284934  |a Neumaier, Michael  |m 1028284934:Neumaier, Michael  |d 60000  |d 63300  |e 60000PN1028284934  |e 63300PN1028284934  |k 0/60000/  |k 1/60000/63300/  |p 5 
998 |g 1153803097  |a Haselmann, Verena  |m 1153803097:Haselmann, Verena  |d 60000  |e 60000PH1153803097  |k 0/60000/  |p 4 
998 |g 1239761503  |a Hetjens, Michael  |m 1239761503:Hetjens, Michael  |d 60000  |d 65200  |e 60000PH1239761503  |e 65200PH1239761503  |k 0/60000/  |k 1/60000/65200/  |p 3 
998 |g 1156311373  |a Thiaucourt, Margot  |m 1156311373:Thiaucourt, Margot  |d 60000  |d 63300  |e 60000PT1156311373  |e 63300PT1156311373  |k 0/60000/  |k 1/60000/63300/  |p 2 
998 |g 1226262503  |a Gerhards, Catharina  |m 1226262503:Gerhards, Catharina  |d 60000  |e 60000PG1226262503  |k 0/60000/  |p 1  |x j 
999 |a KXP-PPN1897205376  |e 4561151907 
BIB |a Y 
SER |a journal 
JSO |a {"language":["eng"],"note":["Gesehen am 31.07.2024"],"relHost":[{"note":["Gesehen am 14.02.13"],"recId":"736559205","physDesc":[{"extent":"Online-Ressource"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"pubHistory":["1.2013 -"],"language":["eng"],"disp":"Heterologous vector-mRNA based SARS-CoV-2 vaccination strategy appears superior to a homologous vector-based vaccination scheme in German healthcare workers regarding humoral SARS-CoV-2 response indicating a high boosting effect by mRNA vaccinesVaccines","title":[{"subtitle":"open access journal","title":"Vaccines","title_sort":"Vaccines"}],"id":{"eki":["736559205"],"issn":["2076-393X"],"zdb":["2703319-3"]},"part":{"volume":"11","extent":"17","issue":"3","pages":"1-17","text":"11(2023), 3 vom: März, Artikel-ID 701, Seite 1-17","year":"2023"},"origin":[{"dateIssuedDisp":"2013-","dateIssuedKey":"2013","publisherPlace":"Basel","publisher":"MDPI"}]}],"physDesc":[{"extent":"17 S.","noteIll":"Illustrationen"}],"recId":"1897205376","name":{"displayForm":["Catharina Gerhards, Margot Thiaucourt, Michael Hetjens, Verena Haselmann, Michael Neumaier and Maximilian Kittel"]},"title":[{"title_sort":"Heterologous vector-mRNA based SARS-CoV-2 vaccination strategy appears superior to a homologous vector-based vaccination scheme in German healthcare workers regarding humoral SARS-CoV-2 response indicating a high boosting effect by mRNA vaccines","title":"Heterologous vector-mRNA based SARS-CoV-2 vaccination strategy appears superior to a homologous vector-based vaccination scheme in German healthcare workers regarding humoral SARS-CoV-2 response indicating a high boosting effect by mRNA vaccines"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"person":[{"given":"Catharina","role":"aut","display":"Gerhards, Catharina","family":"Gerhards"},{"family":"Thiaucourt","display":"Thiaucourt, Margot","role":"aut","given":"Margot"},{"given":"Michael","family":"Hetjens","role":"aut","display":"Hetjens, Michael"},{"given":"Verena","family":"Haselmann","display":"Haselmann, Verena","role":"aut"},{"given":"Michael","family":"Neumaier","display":"Neumaier, Michael","role":"aut"},{"family":"Kittel","display":"Kittel, Maximilian","role":"aut","given":"Maximilian"}],"id":{"eki":["1897205376"],"doi":["10.3390/vaccines11030701"]},"origin":[{"dateIssuedDisp":"19 March 2023","dateIssuedKey":"2023"}]} 
SRT |a GERHARDSCAHETEROLOGO1920